Galectin Therapeutics stock holds recent gains after phase 2b trial update

Published on 09/18/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galectin Therapeutics stock traded around recent highs as of September 17, 2026 after investors focused on data from its phase 2b NASH trial. The company’s latest reported quarterly figures show rising R&D spending alongside a continued net loss.

GALT, US3631621074, Illustration mit AI erstellt.

Galectin Therapeutics stock (ISIN US3631621074) is trading near recent highs as of September 17, 2026, with investors continuing to focus on the company’s experimental therapy for nonalcoholic steatohepatitis and the latest clinical and financial updates from its most recent quarter.

Pipeline data keeps Galectin Therapeutics in focus

Galectin Therapeutics Inc., headquartered in Norcross, Georgia, is a clinical-stage biotechnology company developing galectin inhibitors for liver fibrosis and cancer, with its lead candidate belapectin being evaluated in nonalcoholic steatohepatitis with cirrhosis. In its most recent quarterly update for Q2 2026, the company highlighted ongoing enrollment and follow-up in its phase 2b NASH trial and reiterated its focus on advancing belapectin toward potential registrational studies, underscoring that R&D remains its largest cost block in the current development phase.

According to Galectin Therapeutics in its latest quarterly report for Q2 2026, total operating expenses were dominated by research and development spending associated with the belapectin program, while the company continued to report a net loss for the quarter, typical for a clinical-stage biotech. In the same Q2 2026 period, management reiterated that future cash needs will depend on the pace of clinical development and that additional financing options may be considered, making liquidity and dilution risk key issues for shareholders.

Latest quarterly figures and cash position

In Q2 2026, Galectin Therapeutics reported total revenues that remained minimal, reflecting the absence of an approved commercial product, while net loss widened compared with the same quarter of the prior year as clinical activity increased. According to Galectin Therapeutics, research and development expenses in Q2 2026 rose versus Q2 2025 as the company expanded patient enrollment and monitoring in its NASH cirrhosis study, while general and administrative expenses stayed comparatively stable.

For investors, the balance sheet remains central. Per the same Q2 2026 filing from Galectin Therapeutics, cash and cash equivalents at the end of Q2 2026 were sufficient to fund operations for a defined runway, but management noted that additional capital may be needed to complete later-stage trials, highlighting financing risk as a structural counter-factor to the upside scenario of positive phase 2b data.

Stock price, volatility and investor takeaway

On Nasdaq, Galectin Therapeutics stock recently changed hands at a price level in the low single-digit US dollars as of September 17, 2026, reflecting the typical trading range of a small-cap clinical-stage biotech. This price stands clearly below the kind of double-digit valuations that liver-disease peers can achieve once they move into late-stage registrational programs, underlining how much depends on future belapectin data.